EntRel|05|33||||500|3|||||||||||||||324..498|2|A C$30-a-share bid by Ciba-Geigy Ltd., a pharmaceutical company based in Basel, Switzerland, and California-based Chiron Corp., a bioresearch concern, was extended to Nov. 16||||||||500..540|3|It had been due to expire Friday evening|||||||||||||
Explicit|05|33|552..562|4,1|previously|||previously|||Temporal.Asynchronous.Succession||||Wr|Comm|Null|Null||||135..156;252..320|1,0,0;1,0,1;1,0,3;1,1;1,2|Institut Merieux S.A. said it would extend its bid, due to expire last Thursday, to Nov. 6|Inh|Null|Null|Null||||544..551;563..688|4,0;4,2;4,3|Merieux said it would ensure its bid remained open pending a final decision by Canadian regulators on whether to approve the takeover|Inh|Null|Null|Null|||||||||
EntRel|05|33||||690|5|||||||||||||||544..688|4|Merieux previously said it would ensure its bid remained open pending a final decision by Canadian regulators on whether to approve the takeover||||||||690..805|5|Merieux, a vaccine and bioresearch firm based in Lyon, France, is controlled 50.1% by state-owned Rhone Poulenc S.A|||||||||||||
Explicit|05|33|1091..1095|7,1,2,1,1,1,4,1,1,1,1,2,0|once|||once|||Temporal.Asynchronous.Succession|Contingency.Cause.Reason|||Ot|Comm|Null|Null|998..1030|7,0;7,1,0;7,1,1;7,2|Merieux officials said last week|1064..1090|7,1,2,1,1,1,4,0;7,1,2,1,1,1,4,1,0;7,1,2,1,1,1,4,1,1,0;7,1,2,1,1,1,4,1,1,1,0;7,1,2,1,1,1,4,1,1,1,1,0;7,1,2,1,1,1,4,1,1,1,1,1|the offer will be approved|Inh|Null|Null|Null||||1096..1164|7,1,2,1,1,1,4,1,1,1,1,2,1|it submits details of its proposed investments to federal regulators|Inh|Null|Null|Null|||||||||
Implicit|05|33||||1644|10||while||Comparison.Contrast||||Wr|Comm|Null|Null||||1392..1580|9,1,1|that at the close of business Thursday, 5,745,188 shares of Connaught and C$44.3 million face amount of debentures, convertible into 1,826,596 common shares, had been tendered to its offer|Ot|Comm|Null|Null|1321..1391|9,0;9,1,0;9,2|Institut Merieux, which already holds a 12.5% stake in Connaught, said|1644..1697|10,4,1|11,580 common shares had been tendered to their offer|Ot|Comm|Null|Null|1582..1643|10,0;10,1;10,2;10,3;10,4,0;10,5|At the close of business Thursday, Ciba-Geigy and Chiron said||||||
Implicit|05|33||||1699|11||while||Expansion.Conjunction||||Wr|Comm|Null|Null||||1582..1697|10|At the close of business Thursday, Ciba-Geigy and Chiron said 11,580 common shares had been tendered to their offer|Inh|Null|Null|Null||||1699..1760|11|At last report, Connaught had 21.8 million shares outstanding|Inh|Null|Null|Null|||||||||
Explicit|05|33|1764..1774|12,0|Separately|||separately|||Expansion.Conjunction||||Wr|Comm|Null|Null||||9..131|0|Two rival bidders for Connaught BioSciences extended their offers to acquire the Toronto-based vaccine manufacturer Friday|Inh|Null|Null|Null||||1776..1951|12,1;12,2;12,3;12,4|the Ontario Supreme Court said it will postpone indefinitely a ruling on the lawsuit launched by the University of Toronto against Connaught in connection with the Merieux bid|Inh|Null|Null|Null|||||||||
